DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $38.65.

A number of research firms have recently weighed in on DBVT. Citizens Jmp raised their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a report on Friday. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. HC Wainwright set a $40.00 price target on DBV Technologies in a research report on Thursday, December 18th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Artisan Partners Limited Partnership boosted its position in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after purchasing an additional 3,257,135 shares during the period. Vivo Capital LLC raised its position in shares of DBV Technologies by 133.4% in the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after purchasing an additional 1,407,120 shares during the period. Siren L.L.C. acquired a new stake in shares of DBV Technologies in the fourth quarter worth $35,606,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies in the second quarter worth $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in shares of DBV Technologies during the 2nd quarter worth $9,649,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $20.00 on Friday. The business has a 50 day simple moving average of $21.58 and a 200 day simple moving average of $17.28. DBV Technologies has a 52 week low of $5.30 and a 52 week high of $26.18. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -3.83 and a beta of -0.97.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.96). The business had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.06 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 310.56%. On average, analysts predict that DBV Technologies will post -7.05 EPS for the current year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.